Email this article Pediatric clinical case of parameningeal undifferentiated pleomorphic sarcoma treated with chemoradiotherapy
- Authors: Usychkina A.Y.1, Kobyzeva D.A.1, Gornostaev V.V.1, Loginova A.A.1, Kachanov D.Y.1, Varfolomeeva S.R.1, Roshin V.Y.1, Nechesnyuk A.V.1
-
Affiliations:
- National Scientific and Practical Center of Pediatric Hematology, Oncology and Immunology named after Dmitry Rogachev
- Issue: Vol 16, No 2 (2017)
- Pages: 45-49
- Section: Статьи
- Submitted: 10.08.2018
- Published: 10.06.2017
- URL: https://hemoncim.com/jour/article/view/54
- DOI: https://doi.org/10.24287/1726-1708-2017-16-2-45-49
- ID: 54
Cite item
Full Text
Abstract
Malignant fibrous histiocytoma (MFH) is a rare “NON-RMS-LIKE” pediatric tumor with highly malignant clinical behavior, high metastatic potential and overall 5-year survival around 65-70%. Soft tissue sarcoma diagnostic work-up and optimal combination of systemic therapy and local therapy approaches are one of the most challenging issues in modern pediatric oncology. To present a clinical case of parameningeal undifferentiated pleomorphic sarcoma in 7-year old child treated with adaptive conformal radiotherapy aimed at local tumor control. We describe a method of combined treatment of patient with parameningeal UPS consisting of the intensity-modulated radiotherapy (IMRT) in the form of volumetrically-modulated arc- therapy (VMAT) aimed at local tumor control. The radiotherapy course was completed at the planned total dose of 54 Gy. Acute skin and mucosal toxicity not more than Grade 2 (RTOG scale) was noted during the treatment. A good partial response was recorded after chemoradiotherapy course had been finished. Histological verification of UPS diagnosis is complicated as substantial amount of tumor tissue material is required for immunohistochemical and cytogenetical studies. An aggressive surgical approach is a method of choice for local control in parameningeal soft-tissue sarcomas. However the adaptive radiotherapy was the only possible treatment method of local tumor control with significant decrease of high doses to adjacent normal organs and tissues.
About the authors
A. Y. Usychkina
National Scientific and Practical Center of Pediatric Hematology, Oncology and Immunology named after Dmitry Rogachev
Author for correspondence.
Email: usychkina@gmail.com
ORCID iD: 0000-0001-8313-9056
MD, pediatric oncologist Department of Radiation Therapy
Russia 117997, Moscow, Samory Mashela st., 1 Tel.: +7 (916)-695-0460
Russian FederationD. A. Kobyzeva
National Scientific and Practical Center of Pediatric Hematology, Oncology and Immunology named after Dmitry RogachevRussian Federation
V. V. Gornostaev
National Scientific and Practical Center of Pediatric Hematology, Oncology and Immunology named after Dmitry RogachevRussian Federation
A. A. Loginova
National Scientific and Practical Center of Pediatric Hematology, Oncology and Immunology named after Dmitry RogachevRussian Federation
D. Y. Kachanov
National Scientific and Practical Center of Pediatric Hematology, Oncology and Immunology named after Dmitry Rogachev
ORCID iD: 0000-0002-3704-8783
Russian Federation
S. R. Varfolomeeva
National Scientific and Practical Center of Pediatric Hematology, Oncology and Immunology named after Dmitry RogachevRussian Federation
V. Y. Roshin
National Scientific and Practical Center of Pediatric Hematology, Oncology and Immunology named after Dmitry RogachevRussian Federation
A. V. Nechesnyuk
National Scientific and Practical Center of Pediatric Hematology, Oncology and Immunology named after Dmitry RogachevRussian Federation
References
Supplementary files
